Clinical Trials Browser

Terminated × temsirolimus × Dermatologic × Clear all

NCT01166126 2014-05-15

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

Phase 2 Terminated

4 enrolled 7 charts

Melanoma